ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

NanoString’s CosMx Spatial Molecular Imager Recognized by The Scientist Magazine as a Top 10 Innovation of 2022

Panel of Independent Judges Selects Top New Products in the Life Science Industry

NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced that the company’s CosMx™ Spatial Molecular Imager (SI) has been recognized by The Scientist magazine as one of the Top 10 Innovations of the 2022 (https://www.the-scientist.com/ts-digest/view/the-scientist-top-10-innovations-2022-12-2). This recognition identifies CosMx SMI as a product poised to revolutionize research and advance scientific knowledge with the potential to foster rapid advances and address specific problems in their respective fields.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221213005381/en/

High-resolution RNA imaging of lung tissue. (Graphic: Business Wire)

High-resolution RNA imaging of lung tissue. (Graphic: Business Wire)

CosMx SMI enables high-resolution imaging of more than 1,000 RNA and over 64 protein analytes within morphologically intact whole tissue sections. The CosMx instrument allows researchers to visualize and quantify gene and protein expression at single cell and subcellular resolutions within both fresh frozen and formalin-fixed paraffin-embedded (FFPE) tissue samples. Using a multi-modality approach, including protein imaging, CosMx SMI delivers best-in-class cell segmentation. With high-plex in situ analysis, researchers can perform cell typing, cell state, functional, and cell-cell interaction analyses in a single experiment to generate high-resolution cell atlases.

“The CosMx SMI is the only instrument that has provided us with the opportunity to simultaneously visualize thousands of genes, at subcellular resolution, and across all cells in a tissue,” says Miranda Orr, PhD, an Alzheimer’s disease researcher at Wake Forest University School of Medicine in North Carolina who purchased both NanoString’s CosMx SMI and GeoMx Digital Spatial Profiler (DSP). “We are able to develop maps of the brain at an unprecedented resolution.”

CosMx SMI serves scientists across the continuum of research using a tunable workflow that can prioritize either unbiased whole-slide imaging at high-plex for discovery or high-throughput biology-driven analysis for translational research applications. Researchers can choose from a wide variety of CosMx SMI assays, including pre-defined panels, pre-defined panels combined with custom content, or fully customized assays supporting studies of any species.

The CosMx SMI is the newest product in the company's industry-leading spatial analysis portfolio, joining the GeoMx® DSP. The GeoMx DSP is a fully-automated spatial profiler allowing multi-cellular analysis of whole transcriptome for both human and mouse applications. Both platforms are also customizable for other species.

To learn more about NanoString's CosMx Spatial Molecular Imager, visit www.nanostring.com/CosMx

About NanoString Technologies, Inc.

NanoString Technologies, a leader in spatial biology, offers an ecosystem of innovative discovery and translational research solutions, empowering our customers to map the universe of biology. The GeoMx® Digital Spatial Profiler, cited in more than 170 peer-reviewed publications, is a flexible and consistent solution combining the power of whole tissue imaging with gene expression and protein data for spatial whole transcriptomics and proteomics from one FFPE slide. The CosMx™ Spatial Molecular Imager is an FFPE-compatible, single-cell imaging platform powered by spatial multiomics enabling researchers to map single cells in their native environments to extract deep biological insights and novel discoveries from one experiment. The AtoMx™ Spatial Informatics Platform is a cloud-based informatics solution with advanced analytics and global collaboration capabilities, enabling powerful spatial biology insights anytime, anywhere. At the foundation of our research tools is our nCounter® Analysis System, cited in more than 6,000 peer-reviewed publications, which offers a secure way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision. For more information, visit www.nanostring.com.

NanoString, NanoString Technologies, the NanoString logo, CosMx, GeoMx, AtoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.

Contacts

Doug Farrell

Vice President, Investor Relations & Corporate Communications

dfarrell@nanostring.com

Phone: 206-602-1768

Recent Quotes

View More
Symbol Price Change (%)
AMZN  233.22
+4.06 (1.77%)
AAPL  278.85
+1.30 (0.47%)
AMD  217.53
+3.29 (1.54%)
BAC  53.65
+0.66 (1.25%)
GOOG  320.12
-0.16 (-0.05%)
META  647.95
+14.34 (2.26%)
MSFT  492.01
+6.51 (1.34%)
NVDA  177.00
-3.26 (-1.81%)
ORCL  201.95
-3.01 (-1.47%)
TSLA  430.17
+3.59 (0.84%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.